CITIUS ONCOLOGY, INC. financial data

Symbol
CTOR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
10-Q - Q2 2025 - 12 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 36.01 % +31.7%
Quick Ratio 30.87 %
Debt-to-equity 130 %
Return On Equity -68.38 % -2.7%
Return On Assets -29.7 % -14.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78,370,584 shares +32.3%
Common Stock, Shares, Outstanding 71,552,402 shares +29.6%
Entity Public Float 47,700,000,000,000 USD
Common Stock, Value, Issued 7,155 USD +41.8%
Weighted Average Number of Shares Outstanding, Basic 71,552,402 shares +6%
Weighted Average Number of Shares Outstanding, Diluted 71,552,402 shares +6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6,638,299 USD -17.1%
General and Administrative Expense 11,151,783 USD +1.3%
Operating Income (Loss) -4,944,961 USD -6.8%
Nonoperating Income (Expense) 3,251,554 USD -22%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25,640,941 USD -10.3%
Income Tax Expense (Benefit) 936,720 USD +83.5%
Net Income (Loss) Attributable to Parent -26,577,661 USD -87.5%
Earnings Per Share, Basic 0 USD/shares -100%
Earnings Per Share, Diluted 0 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 112 USD
Inventory, Net 17,208,967 USD
Assets, Current 18,309,079 USD +445.7%
Assets 91,709,079 USD +86.4%
Accounts Payable, Current 8,667,419 USD
Accrued Liabilities, Current 8,458,554 USD +16.4%
Liabilities, Current 52,990,335 USD +16.2%
Deferred Income Tax Liabilities, Net 2,520,720 USD
Liabilities 59,311,166 USD
Retained Earnings (Accumulated Deficit) -59,043,300 USD -18.4%
Stockholders' Equity Attributable to Parent 32,397,913 USD +90.2%
Liabilities and Equity 91,709,079 USD +86.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -191,690 USD -13.6%
Net Cash Provided by (Used in) Financing Activities -24,546,515 USD
Net Cash Provided by (Used in) Investing Activities 24,738,789 USD
Common Stock, Shares Authorized 400,000,000 shares +1.7%
Common Stock, Shares, Issued 71,552,402 shares +29.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 584 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 112 USD
Deferred Tax Assets, Valuation Allowance 4,928,000 USD +21.9%
Deferred Income Tax Expense (Benefit) 264,240 USD +83.5%
Deferred Tax Assets, Operating Loss Carryforwards 7,530,000 USD +62.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares +9%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 91,434,058 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 7,690,104 USD +8.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%